Fiber Intake in an End Stage Renal Disease (ESRD) Population Followed Over 2 Years
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00874380|
Recruitment Status : Completed
First Posted : April 2, 2009
Last Update Posted : May 15, 2013
Our research involves the detailed description of the content of the diet of x dialysis patients.
For our purpose we used a newly developed "food frequency questionnaire". This is the first validated questionnaire specific for dialysis patients and we were the first to use it.
Our special focus was the fiber content in the diet of our patient. Our thesis that they are way below the recommended guidelines for fiber intake was verified. Our follow will evaluate the effect of such at diet, mosTLy cardiovascular.
|Condition or disease||Intervention/treatment|
|Cardiovascular Outcome Kalemia Control Lipid Profile||Other: Increasing total fiber intake in patient's diet|
|Study Type :||Observational|
|Actual Enrollment :||70 participants|
|Official Title:||Fiber Content of Hemodialysis Patients' Diet and it's Cardiovascular Implications.|
|Study Start Date :||October 2008|
|Actual Primary Completion Date :||June 2011|
|Actual Study Completion Date :||June 2011|
First describe the diet of a cohort of dialysis patients with focus on fiber content.
Other: Increasing total fiber intake in patient's diet
Second counsel patients biweekly about their compliance with a high fiber diet, target being 25 to 30 gm of fiber a day.Follow them for a period of 2 years and assess if their is any significant decrease in their cardiovascular events and profile, in addition to assessing the effect of high fiber on kalemia.
- cardiovascular event [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00874380
|United States, New York|
|Staten Island University Hospital|
|Staten Island, New York, United States, 10305|